Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Bone scan limitations in the follow-up of bone metastases from breast carcinoma: A Tunisian center study
Medecine Nucleaire, Volume 36, No. 10, Year 2012
Notification
URL copied to clipboard!
Description
Bone metastases, a relatively frequent complication of breast carcinoma, are more and more associated with better survival. This in part through a specific detection and monitoring. In Sousse (Tunisia), bone scan is the exam most frequently performed for monitoring bone metastases, which is also the only functional exam available until December 2011. We studied the place of bone scan in the monitoring of these bone metastases. We followed 115 patients between 2000 and 2004 with a follow-up of 7 to 11 years. We used Measurable Criteria Disease response of Anderson (MDA) scintigraphic criteria. Complete remission was rare. Partial remission rate decreased gradually over time. Partial remission rate was 22.6% at the first evaluation and became equal to 10% at the fourth assessment. Stability is a false reassuring category since among the 27 cases judged to be stable after the first evaluation, only nine continued to be stable at the fourth evaluation and one at the sixth. In conclusion, bone scan is reliable only in cases of complete or partial remission. For other stages bone scintigraphy had many limitations since this examination informs about the osteoblastic reaction around metastases and not the tumour itself. 18F-FDG-PET/CT ( 18Fluoro-deoxy-glucose) indeed shows the metastasis metabolism itself, so is better positioned to evaluate the therapeutic response. © 2012 Elsevier Masson SAS.
Authors & Co-Authors
Chatti, Kaouthar
Tunisia, Sousse
Chu Sahloul
Harrabi, A.
Tunisia, Sousse
Chu Sahloul
Chabchoub, Imene
Tunisia, Sousse
Chu Sahloul
Kamoun, T.
Tunisia, Sousse
Chu Sahloul
Sfar, Raja
Tunisia, Sousse
Chu Sahloul
Nouira, Manel
Tunisia, Sousse
Chu Sahloul
Ben Fredj, Maha
Tunisia, Sousse
Chu Sahloul
Ayachi, Najla
Tunisia, Sousse
Chu Sahloul
Ben-Ahmed, Slim
Tunisia, Sousse
Chu Sahloul
Essabbah, Habib
Tunisia, Sousse
Chu Sahloul
Statistics
Citations: 10
Authors: 10
Affiliations: 1
Identifiers
Doi:
10.1016/j.mednuc.2012.07.008
ISSN:
09281258
Research Areas
Cancer
Study Design
Cohort Study
Study Locations
Tunisia